Stockreport

TG Therapeutics concludes enrolment in Phase III Briumvi trial [Yahoo! Finance]

TG Therapeutics, Inc.  (TGTX) 
Last tg therapeutics, inc. earnings: 11/12 07:34 am Check Earnings Report
US:NASDAQ Investor Relations: ir.tgtherapeutics.com
PDF Currently approved in the US and selected regions outside the US, Briumvi is now given as a one-hour intravenous (IV) infusion biannually following the initial dose. [Read more]